Glutaredoxin2 reduces age-associated B cell differentiation through maintaining redox homeostasis
Grx2 acts as a redox checkpoint that limits ABC-driven autoimmunity by modulating ROS. The Grx2-ROS axis represents a potential therapeutic target for SLE and related chronic inflammatory diseases.
Authors
- Shihao Tian (ORCID: https://orcid.org/0009-0007-8642-9252)
- Yuan Jiang
- Yatao Du (ORCID: https://orcid.org/0000-0002-6881-0080)
- Fubin Li (ORCID: https://orcid.org/0000-0001-6268-3378)
- Qun He (ORCID: https://orcid.org/0000-0002-2629-1673)
- Haoliang Zhang (ORCID: https://orcid.org/0009-0006-8154-1192)
- Chunli Sun (ORCID: https://orcid.org/0000-0001-9666-9638)
- Yan Zhang (ORCID: https://orcid.org/0000-0002-0437-8348)
- Shujun Liu (ORCID: https://orcid.org/0000-0002-2501-3946)
Institutions
- Shanghai Jiao Tong University (CN)
- XinHua Hospital (CN)
- Ruijin Hospital (CN)
- Ministry of Education (TH)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-10-15
- DOI
- https://doi.org/10.3389/fphar.2025.1593816
- Primary Topic
- Redox biology and oxidative stress
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Shanghai Municipal Health Commission
- National Natural Science Foundation of China
- Karolinska Institutet